==== Front Case Reports Immunol Case Reports Immunol CRII Case Reports in Immunology 2090-6609 2090-6617 Hindawi 10.1155/2020/6694957 Case Report On Two Cases with Autosomal Dominant Hyper IgE Syndrome: Importance of Immunological Parameters for Clinical Course and Follow-Up https://orcid.org/0000-0002-0899-4279Kandilarova Snezhina Mihailova sneji_jm@yahoo.com 1 Lesichkova Spaska Stoyneva 1 Gesheva Nevena Todorova 1 Yankova Petya Stefanova 1 Ivanov Nedelcho Hristov 1 Stoyanova Guergana Petrova 2 Perenovska Penka Ilieva 2 Baleva Marta Petrova 1 Naumova Elissaveta Jordanova 1 1Department of Clinical Immunology with Stem Cell Bank, University Hospital “Alexandrovska”, PID National Expert Center, Medical University, Sofia, Bulgaria 2Department of Pediatric Diseases, University Hospital “Alexandrovska”, Medical University, Sofia, Bulgaria Academic Editor: Claudio Pignata 2020 2 12 2020 2020 66949575 10 2020 8 11 2020 24 11 2020 Copyright © 2020 Snezhina Mihailova Kandilarova et al.2020This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Autosomal dominant hyper-IgE syndrome (AD-HIES) is a rare disease described in 1966. It is characterized by severe dermatitis, a peculiar face, frequent infections, extremely high levels of serum IgE and eosinophilia, all resulting from a defect in the STAT3 gene. A variety of mutations in the SH2 and DNA-binding domain have been described, and several studies have searched for associations between the severity of the clinical symptoms, laboratory findings, and the type of genetic alteration. We present two children with AD-HIES–a girl with the most common STAT3 mutation (R382W) and a boy with a rare variant (G617E) in the same gene, previously reported in only one other patient. Herein, we discuss the clinical and immunological findings in our patients, focusing on their importance on disease course and management. Ministry of Education and ScienceJeffrey Modell Foundation ==== Body 1. Introduction In 1966, Davis et al. [1] published two interesting clinical cases in Lancet: two red-haired white-skinned girls who presented with severe dermatitis several weeks after birth, recurrent cutaneous staphylococcal abscesses, sinusitis, and treatment-resistant pulmonary infections. They named this new nosological entity “Job Syndrome.” None of the parents and siblings shared similar complaints. Six years later, Buckley et al. [2] described two boys with severe dermatitis, a characteristic face, frequent infections, extremely high levels of serum IgE and eosinophilia, and termed the disease “Buckley's syndrome.” In 1974, Hill et al. [3, 4] found that patients with similar diseases had high levels of serum IgE and defects in the chemotactic function of granulocytes. The syndrome was designated as Job's-Buckley syndrome or “Hyperimmunoglobulin E recurrent infection syndrome-HIES.” The disease is autosomal dominant and belongs to the family of primary immune deficiencies (PIDs). In 2004, Renner et al. described six families with different characteristics of hyper IgE syndrome, which was inherited in an autosomal recessive manner [5]. In 2007, genetic defects in the STAT3 were demonstrated in the autosomal dominant form [6, 7], in 2009 in the DOCK8 gene [8] and in 2006–2007 in the TYK2 gene in an autosomal recessive form [9, 10]. Subsequently, several articles reported data on a different number of patients, detecting both established and new mutations [6, 11–15]. In this article, we present 2 children with an autosomal dominant form of HIES (AD-HIES)—a girl with one of the most commonly detected STAT3 mutations and a boy with a very rare mutation in the same gene. We discuss the clinical and immunological findings in patients and the importance of determining the cytokine profile for disease evaluation. 2. Case Presentation 2.1. Case 1 Patient 1 is a 10-year-old male who was born full-term [16]. He has no siblings. Family history for PIDs was negative. Vaccines were given on schedule. Since infancy, he suffered from recurrent staphylococcal skin infections, bacterial otitis at 2 months, subcutaneous abscess of the hairy part of the head at 10 month, and styes of both eyelids at age 3. At age 4, he had pneumonia. At age 8, he developed pleuropneumonia complicated by empyema and pulmonary abscesses with multiple pneumatoceles. Imaging studies of the lungs conducted in the past and during the current examination revealed numerous changes such as emphysema, pneumofibrosis with adhesion, atelectasis, pleural effusions, and partial pneumothorax. Physical examination at admission revealed a polymorphic erythematous rash of the face and eyelids, dry skin with hyperpigmentation on the limbs, onychomycosis of the nails (Figure 1(a)), a dolichocephalic configuration of the head, dysmorphic face (Figure 1(c)), and multiple dental abnormalities: retention, hyperdontia, and alignment of the teeth in two rows (Figure 1(b)). Allergy to nuts, house dust, and cow's milk protein has been proven. Microbiological investigation of sputum/throat smear showed various pathogenic microorganisms such as group A beta-hemolytic streptococci, Moraxella nonliquefaciens, and Streptococcus pneumoniae. Bone density was estimated from spinal densitometry and was age-relevant. The definitive diagnosis was made at age 8. Genetic testing showed a heterozygous variant p.1850 G > A (p.Gly617Glu) in exon 20 of the STAT3 gene, which encodes a transcription factor with key gene regulation activity. According to the criteria of the American College of Medical Genetics, the described variant was categorized as probably pathogenic and, in principal, could explain the observed clinical symptoms. The child was monitored for 4 years after admission. Long-term prophylaxis with Itraconazole 100 mg/day and Sulfamethoxazolum/Trimethoprimum 960 mg daily dose, three times per week, was initiated. A sufficient clinical response was achieved with no severe infections. 2.2. Case 2 Patient 2 is an 11-year-old female, born full-term. She has no siblings and no family history for PIDs. The child was vaccinated with no side effects or complications. No dysmorphic features or skeletal abnormalities were noted; however on the physical examination, hypoplasia of the upper teeth and oral ulcers were observed (Figure 2(a) and 2(b)). Since the age of 1 year, she has been having recurrent fungal infections of the oral cavity, skin, and nails (Candida albicans, Zygomycetes species). The patient has had several manifestations of bronchial obstruction from infancy. At 18 months, she had pneumonia with pleural empyema and subsequent lobectomy. At age 2, she developed diffuse fibrinopurulent peritonitis with necrosis and colon transversum perforation resolved by surgical intervention. At age 2.8, she was hospitalized with hydrothorax and at age 3, was admitted with peritonsillar abscess. At age 4, she had pneumonia and pleuritis and at age 6, retroperitoneal abscess, subphrenic abscess, and diffuse fibrinopurulent peritonitis. The microbiological investigation at that time revealed Candida albicans in feces and throat swab, Proteus mirabilis in abdominal exudate, Klebsiella pneumonia, Acinetobacter baumannii, and Stephanoascus ciferrii in a hemoculture specimen. Densitometric studies revealed that bone density was within the expected for her age. The diagnosis was confirmed at age 7 by the presence of the heterozygous R382W germline mutation in the STAT3 gene. The patient was put on prophylaxis with Itraconazole (10 mg/kg/day) and Sulfamethoxazolum/Trimethoprim at a dose of 480 mg twice per day every other day with relatively good clinical response. Her dermatitis persists despite treatment and prevention (Figure 2(c) and 2(d)). Furthermore, at age 10, hyperplasia of the thymus was observed. However, despite the therapy, in the seventh year of follow-up, there was a worsening of the existing pneumatocele complicated with abscess. Aspergillus fumigatus was isolated from sputum. Hyper IgE Syndrome Scores, according to Grimbacher et al. [17] and STAT3 variants of both cases, are presented in Table 1. Data from immunological tests are shown in Tables 2–4. Written informed consent was obtained from the parents of Patient 1 and from the mother of Patient 2. 3. Discussion 3.1. Increased Serum IgE In 97% of the patients, IgE levels are above 2000 IU/ml [15]. The diagnostic sensitivity of the elevated IgE levels is 95.8%, but the specificity is very low −3.3% [14]. In the course of the disease, a decrease and even a normalization of high serum IgE levels have been observed in some patients [18]. So far, there is no satisfactory explanation for the cause of the extremely high serum IgE levels in patients with AD-HIES. The following hypothesis has been discussed: association with IL-21 signaling [19, 20], low catabolic rate of IgE [21], unconventional way of binding of S. aureus superantigens with MHC class II molecules, the inclusion of a much larger number of T-cell receptors, production of IgE antibodies to staphylococcal superantigens, and massive cytokine production [22–25]. The data concerning food allergy in AD-HIES are controversial: Gernez et al. [26] have found allergy to food in 37% of AD-HIES patients, Siegel et al. [27]–in 8, 5%, Chandesris et al. [15]−8% of AD-HIES patients had asthma and 22%-allergic symptoms mainly food and pollen allergy. Therefore, these reactions are rare in AD-HIES, may possibly be a result of impairment of mastocyte and basophil degranulation, but symptoms of allergy have been described in AD-HIES. This fact points to the importance of diet in these patients, especially in the presence of food allergies. Both patients described by us have elevated levels of IgE (Tables 1 and 2). Patient 1 had a history of rash after oral administration of Amoxicillin/Clavulanic acid, while at the same time allergy to nuts and cow's milk protein has been proven (results not shown). Patient 2 had recurrent pulmonary aspergillosis and showed a trend of increasing IgE levels over the years: from 431 IU/ml at the time of diagnosis to 22 400 IU/ml. In this case, the course of the dermatitis is relatively severe and resistant to treatment. The progressive increase of the disease in Patient 2 might be associated with inadequate infection control and could be a marker of persistent aspergillosis. We suggest that the regular monitoring of IgE titer is important for patients with AD-HIES. 3.2. Hypereosinophilia Hypereosinophilia is due to the increased production of granulocyte-monocyte colony-stimulating factor (GM-CSF) [28, 29]. Eosinophils in the blood are elevated in 70–93% of patients [15], but no correlation was found with IgE levels and clinical symptoms [18]. The diagnostic value of hypereosinophilia in AD-HIES has 93.5% sensitivity, but the specificity is low −23.3% [14]. Mild hypereosinophilia was observed in both patients; however, the higher values in Patient 1 were not related to a worse disease course. The number of eosinophils did not correlate with the measured GM-CSF levels in both cases (Table 3). 3.3. Skin Manifestations The main skin manifestations in AD-HIES are eczema (90%), neonatal rash (45–74%), and skin abscesses (85%) (11, 12, 14, 15). In some cases, the rash is difficult to be distinguished from atopic dermatitis. The typical localization and the presence of lichenified plaques of the anterior neck, antecubital and popliteal fossa in atopic dermatitis come into consideration here. In addition, in AD-HIES, dermatitis is very prolonged, severe, and methicillin-resistant. Involvement of the skin, nails, and mucous membranes in fungal infections is another common manifestation of the disease and is found in 43–85% of patients (11, 12, 14, 15). During infancy, Patient 1 had staphylococcal pyoderma and onychomycosis, but at the same time, he also presented with signs of atopic rash on the flexor surfaces of the limbs and eyelids, drug-induced rash, and allergy to nuts and cow's milk protein. Dermatitis in Patient 2 was persistent, mainly affecting the head and buttocks without a satisfactory therapeutic response. Nails, oral cavity, skin, and intestines were affected by Candida albicans and Zygomycetes spp. 3.4. Pulmonary Manifestations and Severe Infections Pneumonia and pneumatocele are established in 90–100% and in 45–74.5% of patients, respectively (11, 12, 14, 15). Our subjects were suffering from frequent pneumonia and pneumatoceles formation. A more severe course related to pulmonary complications was observed in the case of the common AD-HIES mutation. Life-threatening infections have been observed in 43–89% of patients (12, 14, 15). Patient 1 had empyema and pulmonary abscess. However, Patient 2 presented with more frequent and severe infections and complications. 3.5. Pathologic Dentition and Bone Anomalies They were found in 65–80% of patients (12, 14, 15), but some publications reported lower frequency −27% (11). We observed dental problems in both children, but there were neither abnormalities in bone density nor pathological fractures, scoliosis, or hyperextensible joints. 3.6. Facial Dysmorphism Facial anomalies were visible only in Patient 1. The symptom is important for the diagnosis of the disease and occurs in over 90% of patients (11, 12, 14, 15). Usually, at an earlier age, the dysmorphic manifestations could be quite discrete and become more obvious until puberty. Therefore, in Patient 2, the presence of facial dysmorphism will be evaluated over time. 3.7. STAT3 Mutations Prior to the detection of STAT3 mutations, the diagnosis of HIES was made based on the scoring system [18]. The establishment of a STAT3 pathogenic variant confirms the diagnosis. The STAT3 gene plays an important role in the signal transduction of multiple pro- and anti-inflammatory cytokines [30, 31] and in the differentiation of Th17 cells, respectively, in IL-17 secretion [32]. The variant R382W in Patient 2 (DNA-binding domain) is one of the most common in AD-HIES [12], whereas c.1850 G > A (p.Gly617Glu) mutation (BC6 position of SH2 domain) in Patient 1 has been described only in a 19-year-old man by Schimke et al. [14] in 2010 and “classified as probably damaging.” According to the authors, the G617E variant arose de novo, and the patient presented with a high serum IgE level (>5,000 IU/mL), eczema, scoliosis, skin abscesses, and characteristic facies, without any pulmonary infections, pathologic fractures, or retained primary teeth. Although there is currently no reliable evidence that different mutations correlate with a specific clinical manifestation of the disease [12], patients with SH2 mutations have been reported to have a slightly higher arched palate, widened interalar distance, upper respiratory tract infections, and scoliosis, and those with DNA-binding domain mutations have a higher mortality rate [33]. Both our patients suffer from multiple infections, but in Patient 2, they were more severe. Patient 1 had a typical face dysmorphism. 3.8. Functional Studies on STAT3 Phosphorylation The study of the intracellular STAT3 signaling activation pathway of T cells was performed with the BD Phosflow T-cell activation kit. The expression of phosphorylated STAT3 proteins was determined by flow cytometry. CD4+ and CD8+ cells from both patients were stimulated with IL-6 (100 ng/ml) and labeled with appropriate monoclonal antibodies for surface markers and intracellular phosphorylated proteins. Initially, labeled and unlabeled control beads were used to adjust the fluorescent compensations. Lyophilized control cells were tested as negative and positive controls. Subsequently, patient's samples and samples from corresponding age-matched healthy controls were tested simultaneously. The analysis was performed on FACS Canto II, FACS Diva software. The expression of intracellular phosphorylated proteins resulting from signaling pathway activation was determined by histogram based on the signal from Alexa Fluor 647 antiphosphoprotein antibody. We have determined the geometric mean fluorescence intensity (Geo MFI) value of each signal pathway of unstimulated and stimulated CD4+ and CD8+ T cells. The calculated ratio of Geo MFI stimulated to Geo MFI of unstimulated cells in patient-control pairs was used to estimate the deviation in the STAT3 signaling ability. The results showed that phosphorylation capacity via STAT3 in both patents was lower in comparison to healthy individuals for both CD4+and CD8+ cells (Table 2). 3.9. Immune Cells Subsets STAT3 plays an important role in the regulation of B cells, CD4+, and CD8+ T cells. The differentiation of CD3+CD4+ cells is determined by the activation of the STAT3 pathway and related cytokines. However, the majority of AD-HIES patients did not show significant changes in these cell populations [15, 34]. Patients with AD-HIES were reported to have a decrease of CD4+ T-effector memory cells (TEMs) and an increase of CD4+ T-effector memory RA cells (TEMRAs) [35]. The percentage of T-lymphocytes in both of our patients was within reference values (Table 3). In Patient 1, the percentage of naïve CD4+ T cells (CD45RA+62L+) was significantly reduced, and the effector memory and effector subsets predominated (24.8 and 44.0% of CD4+ T cells, respectively). Siegel et al. [36] showed that STAT3 deficiency leads to a reduction of memory CD8+ T cells, which according to Ives et al. [37], is due to mutations in STAT3 and IL-21R genes. Both of our patients had a decreased percentage of CD8+ T cells with a nearly normal distribution of naïve and memory cells (Table 3). In most studies, memory B cells in AD-HIES patients are reduced [15, 38, 39], and there are no correlations between low memory B cells, the ability for production of antibodies, and accompanied infections [38]. In our study, B cells were within the normal range. A slightly reduced percentage of NK cells was observed in Patient 2 (Table 3). The effects of STAT3 deficiency on NK cells need furder evaluation. The main change in T-lymphocytes associated with dominant negative STAT3 mutations is a low percentage of Th17-cells [14, 15, 30, 40–42]. This population was extremely reduced in our patients as well (Table 3). Several authors [31, 41, 42] showed a great impairment in the ability of Th17 generation in vivo and in vitro to secrete IL-17 and 22 and generation of antigen-specific Th17 to different pathogens. T-cell function assessed by expression of the CD69 marker upon stimulation with phytohaemagglutinin in Patient 1 was retained but remarkably decreased via CD3 receptor pathway in comparison to age-matched healthy controls (2.1% of nonactivated PBMC expressed CD69+ and only 23.6% after T-cell receptor stimulation). At the time of the investigation, Patient 1 was not under corticosteroid or other immunosuppressive therapy. 3.10. Humoral Immunity and Vaccination-Induced Response ANA, IgG, IgA, IgM, and IgG subclasses were normal in both cases. IgE was very high, especially in Patient 2 (Table 3), and a decrease in C4 was also observed. The ASO titer was high in Patient 1 but displayed optimal therapeutic response (results are not shown). Chandesriset et al. [15] described the following changes in serum immunoglobulin levels in AD-HIES patients: high serum IgG in 27%, high serum IgA–in 18%, high serum IgM–in 31%, and high serum IgE–in 96%. Moreover, low serum IgG was detected in 2% of the AD-HIES patients, low IgG1, IgG2, and IgG3–in overall 14%, and low serum IgA–in 13%. According to our data, Patient 1 had a protective level of Pneumococcal Capsular Polysaccharide (PCP) IgG and PCP IgG2, but the level of PCP IgA was decreased. The second patient had decreased protective levels of PCP IgG and PCP IgG2, but PCP IgA was normal. The titers of Haemophilus influenzae type B IgG and Tetanus toxoid IgG in both patients were comparable to those of the majority of children at that age, but the protective titer of antibodies against diphtheria toxoid in both cases was very low (Table 3). According to the literature, 21% of AD-HIES patients in a French study [15] have low antibodies against protein antigens (tetanus, diphtheria, or polio), 7%-low antibodies against S. pneumoniae, but 100%-normal antibodies against Haemophilus influence type B. 3.11. Cytokines STAT3 is the basis of signal transduction of multiple cytokines and growth factors. [43]. On the other hand, STAT3 is involved in the differentiation of Th17 and the production of IL-17. A number of authors reported that in HIES patients, Th17 cells are significantly reduced and IL-17 production is severely impaired [40–42]. IL-17 is known to stimulate neutrophil proliferation and the production of colony-stimulating factor (G-CSF) and epithelial cell IL-8 [31, 44]. An impaired neutrophilic function is one of the main causes of poor response to pathogens, such as streptococci and Candida in patients with HIES. In AD-HIES, an imbalance between Th1 and Th2 responses, decreased production/expression of IFN-γ and relatively increased level/expression of IL-4, defects in IFN-γ and IL-12 signaling pathways, insufficient expression of some chemokines and adhesion molecules have been described and decreased expression of TGF-β and IFN-γ mRNA in circulating activated T-cells [45, 46]. The cytokine production capacity of HIES patients was tested in whole-blood cultures stimulated with heat-killed Staphylococcus aureus, Candida albicans, or a combination of IL-12/IL-18 [47]. The results revealed that IFN-γ production, in addition to IFN-γ/IL-10 ratio, was 10-30-fold lower in the HIES patients compared to the healthy subjects. In contrast, TNF, IL-1β, and IL-8 secretions were normal. The authors concluded that there was an imbalance towards a Th2 phenotype in HIES patients, which possibly contributes to the specific pattern of infections related to this particular PID. Holland et al. [6] demonstrated that the levels of TNF-α, IL-12p70, and IFN-γ produced by PBMC of patients with HIES were elevated in comparison to controls, depending on the stimulus. In our study, we tested the serum levels of 11 proinflammatory and anti-inflammatory cytokines in both patients (Table 4). The serum levels of proinflammatory cytokines (IFN-γ, IL-12p70, IL-1β, TNF-α, IL-18, and IL-6) and IL-2, IL-4, IL-5, GM-CSF in Patient 2 were increased, resembling a “cytokine storm.” After 4 years of symptomatic treatment, the follow-up values of the same cytokines were normal except IL-12p70, IL-1β, IL-6, and IL-18. However, the values were reduced several-fold compared to the previous testing. In the fifth year after the treatment initiation, the levels of IL-2, IL-4, TNF-α, GM-CSF, and IL-18 were elevated again, reflecting some subclinical manifestations and exacerbation of persistent dermatitis. The elevated proinflammatory cytokines TNF-α and IL-6 after 6 years of treatment probably preceded the reported episode of pulmonary complication several months later. In Patient 1, the Th1 profile and a relatively elevated level of IL-4 and GM-CSF predominated at the time of diagnosis. After the initiation of anti-infectious prophylaxis (no severe infections so far), the values of the cytokines became normal except IL-18, which had a sevenfold decrease. In our opinion, the observed changes in cytokines in both patients were mostly associated with concomitant infections. In a patient with the common STAT3 variant who presented with a more severe course, the cytokine disturbance was most significant and persistent over time. The changes in cytokine levels could serve as an important laboratory indicator of therapeutic response to infections and an early marker of recurrence of complications. More studies with a larger number of patients are needed to confirm or reject these considerations. 4. Concluding Remarks Several hundred cases of AD-HIES have been described in the medical literature so far, and few studies have focused on the genotype-phenotype correlations and the changes in humoral and cellular immune response and cytokine profiles. The study participants fulfill the criteria for AD-HIES with an approximately equal score index. However, they presented with different immunological findings and symptom severity, probably due to the functional impact of the individual STAT3 variants. We believe that our comparative approach, based on detailed clinical and laboratory information, will contribute to the enrichment of data for this rare syndrome. In this context, it is important to continue efforts to establish immunological biomarkers that might be predictive or supportive for patient evaluation and management. Acknowledgments The authors acknowledge the patients who participated in this work and their parents for collaboration. The authors acknowledge Anne Puel and Capucine Picard, from Génétique Humaine des Maladies Infectieuses INSERM, France, for genetic testing of Patient 2. The authors acknowledge Assoc. prof. Dr. H. Shivachev, Dr. V. Oparanova, and Dr. I. Tzotcheva from Pirogov Institute for Emergency Medicine, Sofia, for collaboration. The study was funded partially by the National Research Program “Young Scientists and Postdoctoral Fellows” 2019 from the Bulgarian Ministry of Education and Science and by Jeffrey Modell Foundation, USA. Data Availability The data used to support the study are included within the manuscript. Conflicts of Interest The authors declare that there are no conflicts of interest. Authors' Contributions SL, NG, PY, and NI generated laboratory data. PP and GP contributed to the clinical evaluation of patients. SL, NG, PY, SK, and EN aided in the analysis and interpretation of data. SK and MB drafted, reviewed, and revised the manuscript. EN provided critical revision of the article and final approval of the version to publish. Figure 1 Data of some physical manifestations of Patient 1. (a) Onychomycosis of the thumbnail. (b) Retained deciduous teeth at 7 years. (c) Facial features at 11 years. Figure 2 Data of some physical manifestations of Patient 2. (a) Hypoplasia of upper teeth at 7 years. (b) Recurrent oral ulcers at 7 years. (c) Resistant to treatment dermatitis to the scalp. (d) Resistant to treatment dermatitis of the gluteal area. Table 1 Hyper IgE Syndrome Scores and STAT3 mutation data. Symptoms Patient 1 Points Patient 2 Points Highest IgE 2180 IU/ml 10 9740 IU/ml 10 Skin abscesses 3-4 4 3-4 4 Pneumonia 2 4 2 4 Parenchymal lung abnormalities Pneumatocele 8 Pneumatocele 8 Other serious infection Empyema and abscesses pulmonum 4 Abscesses retroperitonealis and subfrenicus dextra 4 Fatal infection Absent 0 Peritonitis, perforation colon transversum 4 Highest eosinophils (109 L) 0.94 6 0, 7 6 Newborn rash Absent 0 Absent 0 Eczema (worst stage) Moderate 2 Moderate 2 Sinusitis/otitis 1–3 1 Absent 0 Candidiasis Finger/nail 2 Systemic 4 Retained primary teeth >3 8 >3 8 Scoliosis, max curve Absent 0 Absent 0 Fractures with little trauma Absent 0 Absent 0 Hyperextensibility Absent 0 Absent 0 Characteristic face Mild 2 Absent 0 Increased nose width (interallar distance) 1-2 SD 1 Absent 0 High palate Present 2 Present 2 Midline anomaly Absent 0 Absent 0 Lymphoma Absent 0 Absent 0 Young age add-on <1 year 7 <1 year 7 SCORE   61   63 STAT3 mutations NM_139276.2(STAT3):с.1850 G > A(p.Gly617Glu)   NM_139276.2 (STAT3):c.1145 G > T (p.Arg382Leu)   Table 2 Evaluation of STAT3 signaling pathway activation in patients. Individuals tested STAT3 activation in CD4+ STAT3 activation in CD8+ Patient 1 CD4+ (U) Geo MFI 5 CD8+ (U) Geo MFI 5 CD4+ (S) Geo MFI 16 CD8+ (S) Geo MFI 17 Geo MFI index 3.2 Geo MFI index 3.4 Healthy control 1 CD4+ (U) Geo MFI 7 CD8+ (U) Geo MFI 5 CD4+ (S) Geo MFI 42 CD8+ (S) Geo MFI 40 Geo MFI index 6 Geo MFI index 8 Patient 2 CD4+ (U) Geo MFI 13 CD8+ (U) Geo MFI 9 CD4+ (S) Geo MFI 32 CD8+ (S) Geo MFI 37 Geo MFI index 2.5 Geo MFI index 4.1 Healthy control 2 CD4+ (U) Geo MFI 139 CD8+ (U) Geo MFI 170 CD4+ (S) Geo MFI 901 CD8+ (S) Geo MFI 971 Geo MFI index 6.5 Geo MFI index 5.7 U: unstimulated; S: stimulated; Geo MFI: geometric mean fluorescence intensity; Geo MFI index: ratio of Geo MFI of stimulated to Geo MFI of unstimulated cells. Table 3 Immunological phenotype of Patients 1 and 2. Immune phenotype/marker (units) Patient 1 Patient 2 Reference range WBC (cells × 109/L) 7.3 7.0 4.5 ÷ 13 ANC (cells × 109/L) 1.97 2.0 1.8 ÷ 8.0 ALC (cells × 109/µL) 3.79 3.8 1.5 ÷ 6.5 Eos (%) 12 10.2 0.0 ÷ 6.0 CD3+ (%Ly) 63 77 66 ÷ 76 CD3+DR+ (%Ly) 9 5∗ 9.5 ÷ 17 CD3+CD4+ (%Ly) 36 45∗∗ 33 ÷ 41 CD45RA+62L+ from CD4+ (%Ly) 24.8∗ 73.6 46 ÷ 99 CD45RA-62L+ from CD4+ (%Ly) 6.4 19.8 0.35 ÷ 100 CD45RA-62L− from CD4+ (%Ly) 24.8∗∗ 4.8 0.27 ÷ 18 CD45RA+62L− from CD4+ (%Ly) 44.0∗∗ 1.8 <1.8 CD3+CD8+ (%Ly) 19∗ 21∗ 27 ÷ 35 CD45RA+62L+ from CD8+ (%Ly) 45.5 68.1 16 ÷ 100 CD45RA-62L+ from CD8+ (%Ly) 5.6 5.9 1 ÷ 6 CD45RA-62L- from CD8+ (%Ly) 23.6 12.4 5 ÷ 100 CD45RA+62L- from CD8+ (%Ly) 25.3 13.6 15 ÷ 41 CD19+ (%Ly) 18 20 12 ÷ 22 CD3-CD16 + 56 (%Ly) 14 6∗ 9 ± 16 CD3+CD16 + 56+ (%Ly) 10 3 4 ÷ 26 CD25+CD127low (%Ly) 8.4 6.2 5 ÷ 10 CD4+CD161+CD196+ (%Ly) 2.34; 2.0∗ 1.2∗ 12.5 ÷ 14.9 IgG (g/l) 16.079 10.64 5.40–16.10 IgG1(g/l) 10.902 8.482 4.23–10.6 IgG2 (g/l) 2.5 2.738 0.72–4.3 IgG3 (g/l) 0.681 0.934 0.127–1.731 IgG4 (g/l) 0.428 0.24 0.016–1.151 IgA (g/l) 1,742 0.75 0.50–2.80 IgM (g/l) 1.400 2.41∗∗ 0.5–1.90 IgE (U/ml)∗∗∗ 2180; 1995; 1104; 1414; 2000∗∗ 431; >2500; 9740; 22400∗∗ <87 Aspergillus fumigates-specific IgE Negative Positive Negative C3 (g/l) 1,557 1.303 0.75–1.65 C4 (g/l) 0.510 0.118∗ 0.20–0.65 ANA (U/ml) 1 : 160 1 : 160 1 : 160 ASO (U/ml) 1066; 522 U/ml∗∗ 12 <200 PCP IgG (mg/L) 85.6 15.4∗ >30 PCP IgG2 (mg/L) 32.0 2.88∗ >11 PCP IgA (mg/L) 1.03∗ 74.6 NA PCP IgM (mg/L) 3.53∗ 209.4 NA Hib IgG (mg/L) 16.5 6.43 >0.15 DT IgG (mg/L) 0.04∗ 0.025∗ >0.1 TT IgG (mg/L) 0.11 0.35 >0.1 ∗Low values; ∗∗high values; ∗∗∗measurement of IgE is in flux with approximately one-year follow-up intervals. WBC: white blood cell count; ANC: absolute neutrophil count; ALC: absolute lymphocyte count; Eos: eosinophils; PCP: pneumococcal capsular polysaccharide; Hib: Haemophilus influenzae type B; DT: diphtheria toxoid; Td: tetanus toxoid; NA: not applicable. The estimation of PCP IgA and IgM values was based on the comparison with the titer of the same antibodies in children tested in our laboratory (data not published). Table 4 Serum levels of cytokines investigated in Patients 1 and 2. Cytokine Concentration (pg/ml)     Patient 1 Patient 2 Reference range∗ At the time of diagnosis, without prophylactic treatment After 2 y of prophylactic treatment At the time of diagnosis, without prophylactic treatment After 4 y of prophylactic treatment After 5 y of prophylactic treatment After 6 y of prophylactic treatment   IFN-gamma 143.85 14.5 244.37 6.47 17.75 3.92 8.08 ± 25.32 IL-12p70 54.46 0.0 50.96 2.83 2.63 0.0 0.90 ± 1.26 IL-13 1.17 0.0 3.81 0.0 0.70 0.56 0.09 ± 0.26 IL1beta 1.76 0.0 47.04 1.32 1.76 0.0 0.09 ± 0.23 IL-2 0.0 0.0 404.17 0.87 7.93 0.0 0.57 ± 1.41 IL-4 8.42 0.0 217.52 0.0 6.59 0.0 0.0 IL-5 1.22 0.0 10.39 0.0 0.61 0.0 0.94 ± 1.26 IL-6 25.71 0.0 18.46 1.70 1.70 3.12 0.07 ± 0.24 TNF-alpha 2.09 0.0 9.64 0.0 6.26 4.17 0.08 ± 0.28 GM-CSF 5.11 0.0 31.46 0.0 23.39 0.0 0.64 ± 1.34 IL-18 113.32 16.0 43.61 22.4 43.52 4.53 1.67 ± 1.75 ∗The values are laboratory specific based on healthy controls tested. ==== Refs 1 Davis S. Schaller J. Wedgwood R. Harvard M. D. Job’s syndrome The Lancet 1966 287 7445 1013 1015 10.1016/s0140-6736(66)9011910.1016/s0140-6736(66)90119-x 2 Buckley R. H. Wray B. B. Belmaker E. Z. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection Pediatrics 1972 49 1 59 70 5059313 3 Hill H. Quie P. Raised serum-IgE levels and defective neutrophil chemotaxis in three children with eczema and recurrent bacterial infections The Lancet 1974 303 7850 183 187 10.1016/s0140-6736(74)92493-3 2-s2.0-0015981727 4 Hill H. Quie P. Pabst H. Defect in neutrophil granulocyte chemotaxis in job’s syndrome of recurrent “cold” staphylococcal abscesses The Lancet 1974 304 7881 617 619 10.1016/s0140-6736(74)91942-4 2-s2.0-0016175385 5 Renner E. D. Puck J. M. Holland S. M. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity The Journal of Pediatrics 2004 144 1 93 99 10.1016/S0022-3476(03)00449-9 2-s2.0-9144261081 14722525 6 Holland S. M. DeLeo F. R. Elloumi H. Z. STAT3 mutations in the hyper-IgE syndrome New England Journal of Medicine 2007 357 16 1608 1619 10.1056/NEJMoa073687 2-s2.0-35348960378 7 Minegishi Y. Saito M. Morio T. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity Immunity 2006 25 5 745 755 10.1016/j.immuni.2006.09.009 2-s2.0-33845897463 17088085 8 Zhang Q. Davis J. C. Lamborn I. T. Combined immunodeficiency associated with DOCK8 mutations New England Journal of Medicine 2009 361 21 2046 2055 10.1056/NEJMoa0905506 2-s2.0-70949098060 9 Minegishi Y. Saito M. Tsuchiya S. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome Nature 2007 448 7157 1058 1062 10.1038/nature06096 2-s2.0-34548317417 17676033 10 Woellner C. Schäffer A. A. Puck J. M. The Hyper IgE syndrome and mutations in TYK2 Immunity 2007 26 5 p. 535 10.1016/j.immuni.2007.05.007 2-s2.0-34248505013 11 Jiao H. Tóth B. Erdős M. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups Molecular Immunology 2008 46 1 202 206 10.1016/j.molimm.2008.07.00110.1016/j.molimm.2008.07.001 18706697 12 Woellner C. Gertz E. M. Schäffer A. A. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome Journal of Allergy and Clinical Immunology 2010 125 2 424 432 10.1016/j.jaci.2009.10.059 2-s2.0-76049116822 13 Fan H. Huang L. Yang D. Pediatric hyperimmunoglobulin E syndrome Medicine 2018 97 14 p. e0215 10.1097/MD.0000000000010215 2-s2.0-85045216183 29620631 14 Schimke L. F. Sawalle-Belohradsky J. Roesler J. Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis Journal of Allergy and Clinical Immunology 2010 126 3 611 617 10.1016/j.jaci.2010.06.029 2-s2.0-77956368467 15 Chandesris M.-O. Melki I. Natividad A. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome Medicine 2012 91 4 e1 e19 10.1097/MD.0b013e31825f95b9 2-s2.0-84863722197 22751495 16 Naumova E. Kyurkchiev D. Clinical Immunology Cases 2019 Sofia Medical University Central Medical Library Press p. 37 17 Grimbacher B. Schäffer A. A. Holland S. M. Genetic linkage of hyper-IgE syndrome to chromosome 4 The American Journal of Human Genetics 1999 65 3 735 744 10.1086/3025470 10441580 18 Grimbacher B. Holland S. M. Gallin J. I. Hyper-IgE syndrome with recurrent infections-an autosomal dominant multisystem disorder New England Journal of Medicine 1999 340 9 692 702 10.1056/NEJM199903043400904 2-s2.0-0033522220 19 Ozaki K. Spolski R. Feng C. G. A critical role for IL-21 in regulating immunoglobulin production Science 2002 298 5598 1630 1634 10.1126/science.1077002 2-s2.0-0037159687 12446913 20 Avery D. T. Ma C. S. Bryant V. L. STAT3 is required for IL-21-induced secretion of IgE from human naive B cells Blood 2008 112 5 1784 1793 10.1182/blood-2008-02-142745 2-s2.0-52649135446 18579794 21 Dreskin S. C. Goldsmith P. K. Strober W. Zech L. A. Gallin J. I. Metabolism of immunoglobulin E in patients with markedly elevated serum immunoglobulin E levels Journal of Clinical Investigation 1987 79 6 1764 1772 10.1172/JCI113017 2-s2.0-0023195781 22 Eberting C. L. Davis J. Puck J. M. Holland S. M. Turner M. L. Dermatitis and new born rash of hyper IgE syndrome Archives of Dermatology 2004 140 1119 1125 10.1001/archderm.140.9.1119 2-s2.0-4544349280 15381553 23 Tiedermann R. E. Fraser J. D. Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation Journal of Immunology 1996 157 3958 3966 24 Travers J. B. Norris D. A. Leung D. Y. M. The keratinocyte as a target for staphylococcal bacterial toxins Journal of Investigative Dermatology Symposium Proceedings 2001 6 3 225 230 10.1046/j.0022-202x.2001.00045.x 2-s2.0-0035756886 25 Leung D. Y. Harbeck R. Bina P. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens Journal of Clinical Investigation 1993 92 3 1374 1380 10.1172/JCI116711 2-s2.0-0027200566 26 Gernez Y. Freeman A. F. Holland S. M. Autosomal dominant hyper-IgE syndrome in the USIDNET registry The Journal of Allergy and Clinical Immunology: In Practice 2018 6 3 996 1001 10.1016/j.jaip.2017.06.041 2-s2.0-85029570324 28939137 27 Siegel A. M. Stone K. D. Cruse G. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation Journal of Allergy and Clinical Immunology 2013 132 6 1388 1396 10.1016/j.jaci.2013.08.045 28 Hashemi H. Mohebbi M. Mehravaran S. Mazloumi M. Jahanbani-Ardakani H. Abtahi S. H. Hyperimmunoglobulin E syndrome: genetics, immunopathogenesis, clinical findings and treatment modalities Journal of Research in Medical Sciences 2017 22 p. 53 10.4103/jrms.JRMS_1050_16 2-s2.0-85018682238 29 Bahaie N. Rao S. Massoud A. Sriramarao P. GM-CSF differentially regulates eosinophil and neutrophil adhesive interactions with vascular endothelium in vivo Iranian Journal of Allergy, Asthma and Immunology 2010 9 207 217 30 Milner J. D. Brenchley J. M. Laurence A. Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome Nature 2008 452 7188 773 776 10.1038/nature06764 2-s2.0-41449110468 18337720 31 Renner E. D. Rylaarsdam S. Aňover-Sombke S. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced TH17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome Journal of Allergy and Clinical Immunology 2008 122 1 181 187 10.1016/j.jaci.2008.04.037 2-s2.0-46049106939 32 Yong P. F. Freeman A. F. Engelhardt K. R. Holland S. Puck J. M. Grimbacher B. An update on the hyper-IgE syndromes Arthritis Research & Therapy 2012 14 6 p. 228 10.1186/ar4069 2-s2.0-84870393179 33 Heimall J. Davis J. Shaw P. A. Paucity of genotype-phenotype correlations in STAT3 mutation positive Hyper IgE Syndrome (HIES) Clinical Immunology 2011 139 1 75 84 10.1016/j.clim.2011.01.001 2-s2.0-79953028378 21288777 34 Zhang L.-Y. Tian W. Shu L. Clinical features, STAT3 gene mutations and Th17 cell analysis in nine children with hyper-IgE syndrome in mainland China Scandinavian Journal of Immunology 2013 78 3 258 265 10.1111/sji.12063 2-s2.0-84882945022 23659370 35 Young T. Y. Jerome D. Gupta S. Hyperimmunoglobulinemia E syndrome associated with coronary artery aneurysms: deficiency of central memory CD4+ T cells and expansion of effector memory CD4+ T cells Annals of Allergy, Asthma & Immunology 2007 98 4 389 392 10.1016/S1081-1206(10)60887-3 2-s2.0-34147209356 36 Siegel A. M. Heimall J. Freeman A. F. A critical role for STAT3 transcription factor signaling in the development and maintenance of Human T cell memory Immunity 2011 35 5 806 818 10.1016/j.immuni.2011.09.016 2-s2.0-82055163110 22118528 37 Ives M. L. Ma C. S. Palendira U. Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8+ T-cell memory formation and function Journal of Allergy and Clinical Immunology 2013 132 2 400 411.e9 10.1016/j.jaci.2013.05.029 2-s2.0-84881121485 38 Speckmann C. Enders A. Woellner C. Reduced memory B cells in patients with hyper IgE syndrome Clinical Immunology 2008 129 3 448 454 10.1016/j.clim.2008.08.002 2-s2.0-55549117115 18835223 39 Avery D. T. Deenick E. K. Ma C. S. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans Journal of Experimental Medicine 2010 207 1 155 171 10.1084/jem.20091706 2-s2.0-76149139419 40 de Beaucoudrey L. Puel A. Filipe-Santos O. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells Journal of Experimental Medicine 2008 205 15 50 10.1084/jem.20080321 2-s2.0-46949086109 41 Ma C. S. Chew G. Y. J. Simpson N. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3 Journal of Experimental Medicine 2008 205 7 1551 1557 10.1084/jem.20080218 2-s2.0-46949089128 42 Milner J. D. Sandler N. G. Douek D. C. Th17 cells, Jobʼs syndrome and HIV: opportunities for bacterial and fungal infections Current Opinion in HIV and AIDS 2010 5 2 179 183 10.1097/COH.0b013e328335ed3e 2-s2.0-76949088006 20543597 43 Levy D. E. Loomis C. A. STAT3 signaling and the hyper-IgE syndrome New England Journal of Medicine 2007 357 16 1655 1658 10.1056/NEJMe078197 2-s2.0-35348961447 44 Jones C. E. Chan K. Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-α , and granulocyte-colony-stimulating factor by human airway epithelial cells American Journal of Respiratory Cell and Molecular Biology 2002 26 6 748 753 10.1165/ajrcmb.26.6.4757 2-s2.0-0036014840 12034575 45 Borges W. G. Augustine N. H. Hill H. R. Defective interleukin-12/interferon-γ pathway in patients with hyperimmunoglobulinemia E syndrome The Journal of Pediatrics 2000 136 2 176 180 10.1016/s0022-3476(00)70098-9 2-s2.0-0003554776 10657822 46 Netea M. G. Kullberg B. J. der Meer J. W. M. Severely impaired IL-12/IL-18/IFNgamma axis in patients with hyper IgE syndrome European Journal of Clinical Investigation 2005 35 11 718 721 10.1111/j.1365-2362.2005.0156410.1111/j.1365-2362.2005.01564.x 16269022 47 Netea M. G. Schneeberger P. M. de Vries E. Kullberg B. J. van der Meer J. W. Koolen M. I. Th1/Th2 cytokine imbalance in a family with hyper-IgE syndrome The Netherlands Journal of Medicine 2002 60 9 349 353 12572706